Lewy body dementia (LBD) is diagnosed through a combination of clinical evaluation, cognitive testing, and specific biomarker tests, but there is no single definitive test for it during a person’s lifetime. Fewer than half of cases confirmed at autopsy were ever correctly diagnosed while the person was alive, making it one of the most underrecognized forms of dementia. Alzheimer’s disease is the most common misdiagnosis.
Getting an accurate diagnosis matters because people with Lewy body dementia can have severe, sometimes dangerous reactions to certain psychiatric medications. Understanding the full diagnostic process can help you advocate for the right workup.
The Four Core Clinical Features
A diagnosis of Lewy body dementia starts with one essential requirement: progressive cognitive decline significant enough to interfere with daily life. But unlike Alzheimer’s, memory loss isn’t usually the earliest or most prominent problem. Instead, the hallmark cognitive deficits involve attention, executive function (planning, organizing, problem-solving), and visual processing. In formal neuropsychological testing, people with early-stage LBD typically perform better on memory tasks than Alzheimer’s patients but worse on tests of attention and visuospatial ability.
Beyond that central feature, clinicians look for four core clinical signs:
- Fluctuating cognition. Pronounced shifts in attention and alertness, sometimes within the same day. A person might seem sharp one hour and confused or drowsy the next.
- Recurrent visual hallucinations. These are typically vivid and well-formed, often featuring people, children, or animals. Many patients can describe exactly what they see, and caregivers sometimes notice the person reacting to things that aren’t there.
- REM sleep behavior disorder (RBD). Acting out dreams during sleep, sometimes violently, by punching, kicking, or shouting. This can begin years or even decades before any cognitive symptoms appear.
- Parkinsonism. Slowed movement, muscle rigidity, or a resting tremor. Over 85% of people with LBD eventually develop at least one of these motor features. Only one needs to be present for it to count toward diagnosis.
If two or more of these core features are present alongside dementia, a diagnosis of probable Lewy body dementia can be made on clinical grounds alone. If only one core feature is present, biomarker testing becomes important.
Biomarker Tests That Strengthen the Diagnosis
Three biomarker tests are classified as “indicative,” meaning a positive result combined with even a single core clinical feature is enough for a probable diagnosis.
The DaTscan is the most widely used. It’s a specialized brain imaging scan that measures dopamine transporter activity in a deep brain region called the basal ganglia. In Lewy body dementia, this activity is reduced because dopamine-producing neurons are damaged. It’s the only FDA-approved imaging agent in the U.S. specifically for distinguishing LBD from Alzheimer’s. An Alzheimer’s brain will typically show normal dopamine transporter uptake; a Lewy body brain will not. The scan can’t, however, distinguish LBD from Parkinson’s disease dementia, since both involve dopamine loss.
A cardiac nerve imaging test measures how well the heart’s nerve supply is functioning. People with LBD often show reduced uptake on this scan because the same protein deposits that affect the brain also damage nerves around the heart. This test is more commonly used in Europe and Japan than in the U.S.
The third indicative biomarker is a sleep study (polysomnography) that objectively confirms REM sleep without the normal muscle paralysis that prevents you from acting out dreams. If a person reports dream-enacting behavior but hasn’t had a formal sleep study, polysomnography can provide that confirmation.
The Role of Skin Biopsy Testing
A newer approach involves testing for abnormal alpha-synuclein protein deposits in skin tissue. Alpha-synuclein is the protein that misfolds and clumps into the “Lewy bodies” that define the disease. Because these deposits also accumulate in nerve fibers throughout the body, a small skin punch biopsy can detect them.
When the right technique is used, this test has shown sensitivity above 80% and specificity approaching 100%, meaning it very rarely produces a false positive. If the test finds phosphorylated alpha-synuclein in your skin, you almost certainly have an alpha-synuclein disease. A negative result is less conclusive, since some studies have found sensitivity as low as 24% depending on the biopsy method. The test is becoming more available but is not yet a routine part of every diagnostic workup.
How It Differs From Alzheimer’s and Parkinson’s
The cognitive profile in LBD looks different from Alzheimer’s from the start. Alzheimer’s typically hits memory and word-finding first. In Lewy body dementia, the earliest struggles tend to involve visual tasks (judging distances, recognizing objects, navigating spaces), sustaining attention, and executive function. Memory is relatively preserved early on. This pattern on neuropsychological testing is one of the strongest clinical clues.
Distinguishing LBD from Parkinson’s disease dementia is trickier because both diseases involve the same abnormal protein. The clinical dividing line is timing: if dementia develops before motor symptoms or within one year of them, the diagnosis is Lewy body dementia. If someone has had Parkinson’s for years and then develops dementia, it’s classified as Parkinson’s disease dementia. This is sometimes called the “one-year rule.” The distinction matters for treatment planning, though the two conditions share significant overlap.
REM Sleep Behavior Disorder as an Early Warning
REM sleep behavior disorder deserves special attention because it can appear 10 to 20 years before any cognitive decline. Up to 90% of people over 50 with this sleep disorder will eventually develop an alpha-synuclein disease, which includes LBD, Parkinson’s, and a rarer condition called multiple system atrophy. In long-term studies, about 73.5% of people with RBD had converted to one of these diseases within 12 years, at a rate of roughly 6.3% per year.
Among those who do convert, about 44% develop Lewy body dementia and about 57% develop Parkinson’s. RBD is present in 68 to 90% of people who already have a Lewy body dementia diagnosis, making it one of the most reliable associated features. If you or a bed partner has been acting out dreams during sleep, this is worth mentioning to a neurologist, especially if there are any accompanying changes in thinking, alertness, or movement.
Genetics and Family History
Lewy body dementia is not primarily a genetic disease, but genetics plays a meaningful role. Roughly 36% of disease risk can be attributed to genetic factors. Three genes have been firmly linked to LBD:
- APOE is the same gene strongly associated with Alzheimer’s risk. It is also the single strongest genetic risk factor for Lewy body dementia.
- GBA carries variants that increase LBD risk by more than eightfold compared to the general population. These same variants are linked to earlier disease onset and shorter disease duration.
- SNCA codes for the alpha-synuclein protein itself. Mutations in this gene were first identified in families with mixed parkinsonism and dementia resembling LBD.
Genetic testing is not part of routine clinical diagnosis for most patients. It’s primarily used in research settings or when there’s a strong family history of multiple members with dementia or parkinsonism.
Why Misdiagnosis Is So Common
Lewy body dementia is the second most common form of degenerative dementia after Alzheimer’s, yet it remains dramatically underdiagnosed. Autopsy studies show that current diagnostic methods have high specificity (doctors rarely diagnose LBD when it isn’t there) but low sensitivity (they frequently miss it when it is). The most common incorrect diagnosis is Alzheimer’s disease.
Several factors drive this gap. The fluctuating nature of symptoms means a person might seem relatively normal during a clinic visit. Visual hallucinations may not appear until later in the disease. Parkinsonism can be subtle, especially early on. And many clinicians default to an Alzheimer’s diagnosis in any older adult with progressive cognitive decline without looking closely at the pattern of deficits or asking about sleep behavior, hallucinations, or fluctuations in alertness.
Seeing a neurologist with specific experience in movement disorders or dementia subspecialties increases the likelihood of an accurate diagnosis. Bringing a detailed symptom log that includes sleep disturbances, episodes of confusion or “zoning out,” visual hallucinations (even brief ones), and any changes in movement or balance gives the clinician much more to work with than a single office visit can reveal.